173 related articles for article (PubMed ID: 17898992)
1. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
3. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
4. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Weinstein D; Simon M; Yehezkel E; Laron Z; Werner H
Diabetes Metab Res Rev; 2009 Jan; 25(1):41-9. PubMed ID: 19145584
[TBL] [Abstract][Full Text] [Related]
5. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
6. Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues.
Lundby A; Bolvig P; Hegelund AC; Hansen BF; Worm J; Lützen A; Billestrup N; Bonnesen C; Oleksiewicz MB
J Appl Toxicol; 2015 Jul; 35(7):842-50. PubMed ID: 25413577
[TBL] [Abstract][Full Text] [Related]
7. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
Ciaraldi TP; Carter L; Seipke G; Mudaliar S; Henry RR
J Clin Endocrinol Metab; 2001 Dec; 86(12):5838-47. PubMed ID: 11739448
[TBL] [Abstract][Full Text] [Related]
8. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
9. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties.
Kellerer M; Häring HU
Exp Clin Endocrinol Diabetes; 2001; 109(1):63-4. PubMed ID: 11573144
[No Abstract] [Full Text] [Related]
10. Mitogenic potency of insulin glargine.
Zełobowska K; Gumprecht J; Grzeszczak W
Endokrynol Pol; 2009; 60(1):34-9. PubMed ID: 19224503
[TBL] [Abstract][Full Text] [Related]
11. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.
Hansen BF; Danielsen GM; Drejer K; Sørensen AR; Wiberg FC; Klein HH; Lundemose AG
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):271-9. PubMed ID: 8670118
[TBL] [Abstract][Full Text] [Related]
12. Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells.
Wu YC; Zhu M; Robertson DM
PLoS One; 2012; 7(8):e42483. PubMed ID: 22879999
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
14. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
15. Role of insulin-like growth factor 1 receptor and c-Src in endothelin-1- and angiotensin II-induced PKB phosphorylation, and hypertrophic and proliferative responses in vascular smooth muscle cells.
Bouallegue A; Vardatsikos G; Srivastava AK
Can J Physiol Pharmacol; 2009 Dec; 87(12):1009-18. PubMed ID: 20029537
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
Wada T; Azegami M; Sugiyama M; Tsuneki H; Sasaoka T
Diabetes Res Clin Pract; 2008 Sep; 81(3):269-77. PubMed ID: 18585815
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells.
Oleksiewicz MB; Bonnesen C; Hegelund AC; Lundby A; Holm GM; Jensen MB; Krabbe JS
J Appl Toxicol; 2011 May; 31(4):329-41. PubMed ID: 20936651
[TBL] [Abstract][Full Text] [Related]
18. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Kurtzhals P; Schäffer L; Sørensen A; Kristensen C; Jonassen I; Schmid C; Trüb T
Diabetes; 2000 Jun; 49(6):999-1005. PubMed ID: 10866053
[TBL] [Abstract][Full Text] [Related]
19. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities.
Ciaraldi TP; Sasaoka T
Horm Metab Res; 2011 Jan; 43(1):1-10. PubMed ID: 20938889
[TBL] [Abstract][Full Text] [Related]
20. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells.
Bähr M; Kolter T; Seipke G; Eckel J
Eur J Pharmacol; 1997 Feb; 320(2-3):259-65. PubMed ID: 9059862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
